



Endologix  
Investor Relations Department  
2 Musick  
Irvine, CA 92618  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: ELGX

|               |                                                    |
|---------------|----------------------------------------------------|
| Last Trade:   | 4.06                                               |
| Trade Time:   | 4:00 PM ET<br>Mar 23, 2018                         |
| Change:       | -0.18 <span style="color: red;">↓</span> (-4.245%) |
| Day Range     | 4.05 - 4.38                                        |
| 52-Week Range | 3.75 - 7.66                                        |
| Volume        | 301,013                                            |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- Addressing a signi... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

Mar 19, 2018

[Endologix Reports Positive Results from Global ENCORE Analysis with Polymer Endovascular Aneurysm Repair \(EVAR\) Using Ovation Abdominal Stent Graft Systems](#)

Mar 5, 2018

[Endologix, Inc. Announces Enrollment of the First Patient in EVAS2 IDE Clinical Study of the Nellix® EndoVascular Aneurysm Sealing System](#)

Feb 21, 2018

[John McDermott Steps Down as Chief Executive Officer of Endologix, Inc.](#)

Feb 21, 2018

[Endologix Reports Fourth Quarter and Fiscal Year 2017 Financial Results](#)

Feb 5, 2018

[Endologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical Study](#)

### Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

Mar 13, 2018

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)